Tempest Therapeutics
Price & Volume
Stats
See more52W Range | $5.34-$20.67 |
Market Cap | $41.3M |
Shares Short | 173,516 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$14.52 |
News
See moreYahoo Finance • 2 months ago
Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.58
Yahoo Finance • 2 months ago
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Yahoo Finance • 3 months ago
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Yahoo Finance • 4 months ago
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
About
CEO | Mr. Stephen R. Brady J.D., LLM |
CFO | Mr. Nicholas Maestas |
Address | 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 21 |
